Vitronectin is one of the major extracellular matrix proteins that accumulates in atherosclerotic lesions. A monoclonal antibody (EMR1a/212D) specifically stained the extracellular regions in thickened intima which colocalized well with lipid deposition. The antigenic glycoprotein with a molecular weight of 66KDa was revealed to be rabbit vitronectin. When homogenates of WHHL rabbit atheroma were subjected to immunoblot analysis using EMR1a/212D, four molecules with molecular weight 66, 56, 50 and 47KDa were detected.
Vitronectin is one of the major extracellular matrix proteins that accumulates in atherosclerotic lesions. A monoclonal antibody (EMR1a/212D) specifically stained the extracellular regions in thickened intima which colocalized well with lipid deposition. The antigenic glycoprotein with a molecular weight of 66KDa was revealed to be rabbit vitronectin. When homogenates of WHHL rabbit atheroma were subjected to immunoblot analysis using EMR1a/212D, four molecules with molecular weight 66, 56, 50 and 47KDa were detected.
To confirm whether these smaller immunopositive bands were derived from mature vitronectin, another monoclonal antibody (EMR1b/244H) recognizing the polypeptide region of vitronectin was prepared. All four molecules were detected by EMR1b/244H as well as by EMR1a/212D. Two smaller vitronectins (56KDa and 5OKDa) were found in atherosclerotic lesions and increased markedly during the development of atherosclerosis.
On the other hand, the vitronectin detected in normal rabbit aorta was mainly of the mature type, while 56KDa and 47KDa forms were not detected.
The total amount of the four vitronectins in atherosclerotic lesions was 38.5kigou+5.0 ng/mg wet weight tissue, a value approximately 9.5 fold higher than that found in normal aorta. In conclusion, we found massive accumulation of these vitronectins concomitant with atherosclerotic development in rabbit aorta.
J Atheroscler Thromb, 1996 ; 3 : 25-31. -hyperlipidemic (WHHL) rabbits as a complex mixture of immunogens (1, 2). Using one of these antibodies (EMR1a/ 212D), the extracellular regions in atherosclerotic lesions showed good correspondence immunohistochemically with the area of lipid deposition but not with the foam cells (1). The antigenic material was rabbit vitronectin (66KDa) that was deduced from 76% amino acid homology to human vitronectin (3). Sialic acids in the sugar chains of vitronectin were necessary for recognition by this antibody. Vitronectin is known as a multifunctional adhesive protein which promotes cell attachment (4, 5) and which interacts with glycosaminoglycan and proteoglycan (6, 7). During the development of atherosclerosis, smooth muscle cells migrate and proliferate in atherosclerotic intima. Vitronectin might be involved in the spreading of smooth muscle cells and modulate the cell function. Vitronectin is also capable of binding to C5b-7 complement complex (8, 9) , plasminogen activator inhibitor-I (10, 11) and thrombin-antithrombin III complex (12) . The association of vitronectin with these molecules seems to play a some role in the arterial wall to 
Results
Preparation of monoclonal antibody EMR1b/244H recognizing the polypeptide region of vitronectin We prepared an anti-desialilated vitronectin antibody (EMR1b/244H). To confirm the recognition of the peptide portion of vitronectin by EMR1b/244H, its reactivity to recombinant vitronectin expressed in E. coli was examined by immunoblot analysis (Fig. 1A) . EMR1b/244H reacted to both the recombinant vitronectin (60KDa) and the purified vitronectin (66KDa). The molecular size of the recombinant vitronectin was almost the same as the product of glycanase treated 66KDa vitronectin (3). A band stained at 26KDa was nonspecific since a similar band was also detected in the control E coil lysate. In contrast, EMR1a/212D, that requires sialic acids for recognition reacted with the purified vitronectin but not with the recombinant vitronectin (Fig . 1B) . 
Vitronectins in atherosclerotic aorta
The molecular size and amount of vitronectin in atherosclerotic aorta were analyzed by immunoblotting . As shown in Fig. 3A : 66, 56, 50 and 47KDa polypeptides were detected in atherosclerotic aorta using the EMR1b/244H antibody . The 56 and 50KDa polypeptides were major bands in all preparations from WHHL rabbits, but the amount of 66 and 47KDa polypeptides varied according to the preparation. The 56KDa polypeptide, which was found abundantly in atherosclerotic aorta, was not detected in normal aorta, or in the normal or WHHL rabbit sera. When these bands were calculated densitometrically (Fig. 4) , the amount of 56KDa vitronectin was between 16.8-36.1 ng/mg wet weight tissue, corresponding to 44-80% of total vitronectin in atherosclerotic aorta Another form of vitronectin (50KDa), was also found to be significantly accumulated (5.3-8.2 ng/mg wet weight) in atherosclerotic aorta By comparison , the amount of 66KDa polypeptide present in atherosclerotic aorta was small (0-15.3 ng/mg), though the polypeptide occupied a major part in normal aorta (2.6-4.2 ng/mg). The total vitronectins in atherosclerotic aorta (38.5+5.0 ng/mg) increased 9.5 fold above the level found in normal aorta (4.1+ 0.9 ng/mg) (Fig. 4) .
When the EMR1a/212D antibody was used, the 66, 56 , 50 and 47KDa polypeptides were again all detected in atherosclerotic aorta (Fig. 3B) . The 56 and 50KDa polypeptides in atherosclerotic aorta increased in significantly comparison with those in normal aorta. Their distribution profile in Fig. 1 atherosclerotic aorta was essentially the same as that observed with EMR1b/244H antibody (data not shown, see Fig. 3B ). These results suggest that in atherosclerotic aortae the 56KDa polypeptide, which was not detected in normal aorta, or in the normal and WHHL sera, mainly contributed to the 9.5-fold increase in the level of vitronectin.
Vitronectins in different sections of arterial wall In WHHL rabbits, atheroma often develops more severely in the aortic arch and less severely in the abdominal aorta (15, 16 ). An atherosclerotic aorta was removed and cut into 2 cm sections as illustrated in Fig. 5 . In sections A to C, the 66, 56, 50 and 47KDa polypeptides were detected by EMR1b/244H, but were not found in section D (Fig. 5A) . Normal and WHHL rabbit sera were subjected to 10% SDS-PAGE and immunoblot analysis. The filters were reacted for 25 min on agarose gel containing the substrate. The relative amounts of vitronectins were measured by densitometric scanning of reactions products. The values were calculated from purified 66KDa vitronectin as standard and expressed as ng equivalent to 
Discussion
We have previously shown by using a monoclonal antibody EMR1a/212D recognizing sialic acids in the glycosylated regions of vitronectin, that vitronectin accumulates significantly in the extracellular regions where lipids are deposited in the atherosclerotic aorta of WHHL rabbits (1-3). Biochemical characterization of vitronectin deposited in atherosclerotic aorta may help in understanding the role of vitronectin in atherosclerotic lesions. In this study, a new monoclonal antibody EMR1b/244H, recognizing the polypeptide region of vitronectin, was prepared. The recognition of the polypeptide region of vitronectin by EMR1b/244H was confirmed by immunoblot analysis in which the antibody reacted with the 60KDa recombinant vitronectin (Fig. 1A) , because E. coli does not modify polypeptides with N-linked and 0-linked sugar chains.
Using this EMR1b/244H antibody, several molecular sizes of vitronectin, such as 66, 56, 50 and 47KDa were detected (Fig. 3A) . The 56 and 50KDa polypeptides were markedly increased in WHHL rabbit aortae (Fig. 4) , and the amount of these vitronectins detected were correlated to the amount of cholesterol (Fig. 5 and Table 2 ). Both the major 56KDa and the minor 47KDa components of vitronectin were detected only in WHHL rabbit aorta but not in normal aorta or in either rabbit sera (Figs. 2 and 3) .
Using EMR1a/212D which recognizes the sialic acids of sugar chains of vitronectin as an epitope, the four polypeptides : 66, 56, 50 and 47KDa were also detected by immunoblot staining (Fig. 3B) . The specificity of the two antibodies, EMR1a/212D and EMR1b/244H against these four components found in atheroma was essentially the same. This result suggests that the four vitronectin molecules had an epitope against EMR1a/212D as well as that against EMR1b/244H. In other words, all four vitronectins seem to have similar sugar chains containing sialic acids as the mature vitronectin in serum, since reactivities of EMR1a/ 212D against those molecules were almost the same . It should be noted that Fig. 2B was exposed much longer than Fig. 2A in order to confirm the presence of the 50KDa band in the sera. Therefore the 50KDa band seemed to be less reactive to EMR1a/212D than to EMR1b/244H. The possibility that the 50KDa band is different from the 50KDa found in atheroma cannot be ruled out. It may be possible that the 66KDa polypeptide originates from the plasma, whilst the other components might arise in the arterial wall, since two other components (56 and 47KDa) were detected only in the atherosclerotic aorta and not in the serum.
It is known that the source of serum vitronectin is the liver , since vitronectin mRNA has mainly been detected there (17) . It has been shown that endothelial cells transcytose vitronectin-thrombin-antithrombin complex, depositing the complex into the subendotherial matrix (18) . Considering different distribution profiles of vitronectin in atherosclerotic aorta from that in serum, it seems clear that serum vitronectin receive some modification during accumulation in atherosclerotic aorta by proteolytic cleavage and/or partial removal of sugar chains. Proteolytic cleavage seems to occur in atherosclerotic aorta because the mere elimination of sugar chains does not explain the decrease in the molecular weights of these smaller vitronectins. Such modification of vitronectin may occur in part in serum as well. Recent studies have shown that human vitronectin was cleaved by plasmin at 95 amino acids upstream from the C terminus (19) . This cleavage site is in the heparin binding domain of vitronectin and is different from the endogenous cleavage site Arg379 (20) . It is possible that plasmin and/or other protease cleaves the cationic charged domain (heparin binding domain) of the vitronectin to make lipophilic subtypes, which could interact with the cholesteryl ester accumulating in atherosclerotic lesions. It is, however, unclear whether the smaller vitronectins we found contain even a part of the heparin binding domain. A possibility that these vitronectins are specifically synthesized in atherosclerotic aorta is not likely, since we failed to detect mRNA of vitronectin in the arterial wall in normal and WHHL rabbits either by an in situ hybridization technique or by northern blot analysis (data not shown). Recently, Seiffert et al. reported that mouse vitronectin mRNA could not be detected in mouse aorta by northern blot analysis (21) . However, there remains a possibility that these polypeptides may be derived from platelets deposited in the arterial wall (22) . Further study is required to clarify why these modified vitronectins are deposited in atherosclerotic lesions.
It is known that vitronectin exhibits a number of biological activities, such as cell adhesion (23, 24) , binding of heparin (6, 7) and collagen (25) , association with PAI-I (10, 11) and stabilized PAI-I-vitronectin complex (26) (27) (28) . Recently, several reports have shown that vitronectin induces haptotaxis of vascular smooth muscle cells (29) . The modification of the vitronectin may change its biological activities. Whether the production of smaller vitronectins leads to the progression of atherosclerosis as well as its accumulation in the lesion is for future investigation.
In conclusion, we detected four different sizes of vitronectin (66, 56, 50 and 47KDa) in atheroma, and found that the amounts of the 56 and the 50KDa polypeptides were greatly increased. This is, to our knowledge, the first report that shows the unique biological feature of vitronectin in atherosclerotic lesions. Further study is required to elucidate the pathophysiological function of these various sizes of vitronectin. 
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